Our History

Cost-effective, unmatched capacity, and unparalelled turnaround times A wholly-owned subsidiary of Opentrons Labworks, PRL launched in 2020 in response to the COVID-19 pandemic to address the pressing need to make rapid, accurate and low-cost testing equitably accessible to all populations. By integrating Opentrons’ leading laboratory automation, together with world-renowned scientific expertise, PRL has revolutionized the PCR testing process by reducing the cost and increasing the speed and accuracy of COVID-19 testing. In addition to diagnostic PCR testing, PRL’s CLIA-certified laboratories perform non-diagnostic, whole genome sequencing services to detect and track SARS-CoV-2 variants in real time and inform both public and private health responses. PRL’s fast and cost-efficient clinical testing services are designed to set new standards in disease diagnostics to better inform treatment guidelines and health outcomes.

We’re a market newcomer, but we have decades of experience in this industry

PRL is led by a team of experts in genetics, clinical diagnostics, and robotics. PRL’s state-of-the-art labs use knowledge and technology licensed from NYU Langone based on research led by world-class geneticist Dr. Jef Boeke. PRL is a subsidiary of Opentrons Labworks Inc., a leading diagnostic life sciences company based in Brooklyn, NY.

Scientific Advisory Board

Jef Boeke, PhD

CHAIR

Peter Palese, PhD

BOARD MEMBER

Orly Ardon, PhD

BOARD MEMBER

Michael Glickman, MD

BOARD MEMBER

Chris Mason, PhD

BOARD MEMBER

Rahul Satija, PhD

BOARD MEMBER

Matija Snuderl, MD

BOARD MEMBER

Jay Varma, MD

Advisor